Status | Study |
Not yet recruiting |
Study Name: 18F-FDG PET/CT-based Prognostic Model for Predicting Outcome in Patients With Peripheral T-cell Lymphoma Condition: Lymphoma, T-Cell, Peripheral Date: 2017-02-09 Interventions: Device: 18F-FDG PET/ CT 18F-FDG PET/CT will be conducted before, during and after chemotherapy. Patients |
Not yet recruiting |
Study Name: Evaluating 18F-FDG PET/CT With Liver SUVmax-based Criteria for Prognosis of Patients With Peripheral T-cell Lymphoma Condition: Lymphoma, T-Cell, Peripheral Date: 2017-02-09 Interventions: Device: 18F-FDG PET/CT 18F-FDG PET/CT will be conducted before, during and after chemotherapy. Patients |
Not yet recruiting |
Study Name: Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients Condition: Peripheral T Cell Lymphoma Date: 2016-11-03 Interventions: Drug: chidamide 30mg po twice |
Completed |
Study Name: A Retrospective Study of Clinical, Phenotypic and Genetic Factors of Peripheral T-Cell Lymphomas Condition: Lymphoma, T-Cell, Peripheral Date: 2016-05-23 Interventions: Other: No Intervention |
Recruiting |
Study Name: Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell Lymphoma Condition: Lymphoma, T-Cell, Peripheral Lymphoma, T- Date: 2015-09-03 Interventions: Drug: RP6530 Tablet starting at 200 mg Other Name: P |
Recruiting |
Study Name: Study of MK-3475 in Relapsed or Refractory Peripheral T-cell Non-Hodgkin Lymphoma Condition: Lymphoma, T-Cell, Peripheral Date: 2015-08-26 Interventions: Drug: MK-3475 Other Name: Pembrolizumab |
Recruiting |
Study Name: Endostar Aggressive Treatment of Peripheral T-cell Lymphoma (PTCL) Phase II Clinical Study Condition: Peripheral T-cell Lymphomas Date: 2015-07-26 Interventions: Drug: GDP GDP is a a combinati |
Active, not recruiting |
Study Name: Open-label, Phase II Study of MLN9708 in Patients With Relapsed/Refractory Cutaneous and Peripheral T-cell Lymphomas Condition: Lymphoma, T-Cell Date: 2014-06-05 Interventions: Drug: MLN9708 |
Completed |
Study Name: Intensive Chemo-immunotherapy as First Line Treatment in Adult Patients With Peripheral T- Cell Lymphoma Condition: Lymphoma, T-Cell, Peripheral Date: 2012-08-30 Interventions: Procedure: Clin A. CHOP-CAMPATH (Chemo-immunotherapy) + SCT |
Completed |
Study Name: A Pilot Study of Sorafenib Examining Biomarkers in Refractory or Relapsed T-Cell Lymphoma Patients Condition: T Cell Lymphoma Date: 2012-03-13 Interventions: Drug: Sorafenib Intrapatient dose reduction to 400 mg once daily and then 400 mg every other day will be |